Stay updated with breaking news from Patrick Mcenany. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Key Insights Significantly high institutional ownership implies Catalyst Pharmaceuticals' stock price is sensitive to...
CORAL GABLES, Fla., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company, today announced that Patrick J. McEnany, Founder, Chairman and CEO of Catalyst, has been bestowed the 2023 Lifetime Achievement Award by BioFlorida at their Annual Meeting last Friday. This prestigious award highlights Mr. McEnany's outstanding accomplishments, unwavering commitment to rare disease patients, dedication to Cat
By Colin Kellaher Catalyst Pharmaceuticals co-founder Patrick McEnany, who has been at the helm of the drugmaker since its inception in early 2002, plans to...
Drug developer Santhera Pharmaceuticals agreed to the deal to license vamorolone to Catalyst for $75 million, plus an equity investment.
Catalyst Pharmaceuticals (CPRX) "hit the ball out of the park" in the first quarter, says Chief Executive Patrick McEnany. But CPRX stock fell after earnings…